Canadian Corporate News - Biovail Receives Approval for Wellbutrin(R) XL to Treat Depression in Canada.
TORONTO, Jan 17, 2006 (CCNMatthews via COMTEX) — Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that the Therapeutic Products Directorate Canada (TPD) has issued a Notice of Compliance (NOC) for 150mg and 300mg tablet strengths of Wellbutrin(R) XL, a once-daily, extended-release formulation of bupropion hydrochloride (HCl) for the treatment of major depressive illness in adults.
Upon launch, Wellbutrin(R) XL will be the first and only once-daily formulation of bupropion available in Canada.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
In the interest of the patient: Convergence across the pharmaceutical and healthcare industries
Biovail Pharmaceuticals Canada (BPC), Biovail’s Canadian sales and marketing …
Read the rest of this article with a Free Trial at HighBeam Research.
